Posts by Raymond J. March
Raymond J. March is a Research Fellow and Director of FDAReview.org with the Independent Institute. He is also an Assistant Professor of Economics at Angelo State University where he is the Assistant Director of the Free Market Institute, Assistant Research Professor at Texas Tech University, Public Choice and Public Policy fellow with the American Institute for Economic Research, and an affiliated scholar with the Challey Institute for Global Innovation and Growth. His research has appeared in Health Economics, Southern Economic Journal, Public Choice, Research Policy, Food Policy, Journal of Institutional Economics, The Independent Review and other academic outlets. His popular articles have appeared in Fortune, Washington Examiner, National Interest, Washington Times, Sun Sentinel, The Hill, Real Clear Health, Medical News Daily. He earned his Ph.D. from Texas Tech University.
Will FDA Approve Biogen’s Promising New Treatment for Alzheimer’s?
Raymond J. March  •  Thursday, January 16, 2020
Only Markets Can Alleviate Drug Shortages
Raymond J. March  •  Tuesday, December 3, 2019
New FDA Commissioner, Same FDA Problem
Raymond J. March  •  Monday, November 25, 2019
Telemedicine Continues to Reach New Heights
Raymond J. March  •  Wednesday, November 6, 2019
Breakthrough Alzheimer’s Drug Puts FDA’s Drug-Approval Process into Question
Raymond J. March  •  Tuesday, October 29, 2019
Is Right-to-Try Legislation a Bust? Time for a Second Opinion.
Raymond J. March  •  Thursday, October 17, 2019
Trust Walmart’s Insulin to Save Lives
Raymond J. March  •  Tuesday, August 27, 2019
FDA Investigates Supposed Link Between Vaping and Seizures
Raymond J. March  •  Tuesday, August 20, 2019
How Government Prolonged the Lobotomy
Raymond J. March  •  Friday, August 16, 2019
New Study Finds FDA in Contempt of the U.S. Constitution
Raymond J. March  •  Thursday, August 1, 2019
Worried About Big Pharma? Then Reduce the FDA’s Regulatory Power.
Raymond J. March  •  Monday, July 29, 2019
As Insulin Prices Rise, Diabetics Turn to Black Markets
Raymond J. March  •  Tuesday, July 9, 2019
San Francisco’s Vaping Ban Is Doomed To Go Up in Smoke
Raymond J. March  •  Tuesday, July 2, 2019
Trump’s Executive Orders Won’t Lower Healthcare Prices, but Deregulation Will
Raymond J. March  •  Thursday, June 27, 2019
Right-to-Try Legislation Helps Patient Battling Bone Cancer
Raymond J. March  •  Monday, June 24, 2019
FDA Approves $2 Million Drug. Blame the Price on Excessive Regulation.
Raymond J. March  •  Thursday, May 30, 2019
FDA To Stop Regulating the Amount of Cherries in Frozen Cherry Pie
Raymond J. March  •  Wednesday, May 15, 2019
Political Rhetoric Against Right-to-Try Laws Continues, Undermining Support for Medical Treatments of Last Resort
Raymond J. March  •  Tuesday, May 7, 2019
FDA Approves Ketamine-Based Drug to Treat Difficult Cases of Depression
Raymond J. March  •  Thursday, March 28, 2019
Generic Insulin Now Available After Nearly One Hundred Years of Regulatory Protection From Competition
Raymond J. March  •  Tuesday, March 26, 2019
FDA Wants More Sunscreen Regulations, but Would Consumers Get Burned?
Raymond J. March  •  Thursday, March 14, 2019
FDA Panel Backs Ketamine-Based Treatment for Depression
Raymond J. March  •  Wednesday, February 27, 2019
Let Competition, Not Politicians, Bring Insulin Prices Down
Raymond J. March  •  Wednesday, February 20, 2019
Right-to-Try Laws Help Patient with Terminal Brain Cancer
Raymond J. March  •  Friday, February 1, 2019
FDA Approves Record Number of Generic Drugs in 2018
Raymond J. March  •  Wednesday, January 9, 2019
« Newer Posts
Older Posts »
  • Catalyst
  • Beyond Homeless
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org
© 2024 INDEPENDENT INSTITUTE, 100 SWAN WAY, OAKLAND CA 94621-1428 | (510) 632-1366 | (510) 568-6040 FAX | SEND EMAIL